Synvista Therapeutics Posts Letter to Stockholders o...( MONTVALE N.J. Sept. 17 /- Synvist...)

MONTVALE, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) today announced that a Letter to Stockholders is now posted to the Company's Web site http://www.synvista.com. The text is as follows:

To Our Stockholders:

The team at Synvista Therapeutics has made tremendous progress in our efforts to deliver on the promise of personalized medicine, and to redefine the treatment of cardiovascular disease in diabetics as well as the treatment of other diseases in the general population. Since my last letter in August 2007, our clinical trials with SYI-2074 for the treatment of heart disease in diabetics had inconclusive results, and we opted not to move forward with the compound's development in this indication. However, we have a robust pipeline on which we are building our business. We have:

-- Advanced our Haptoglobin (Hp) diagnostic test.

-- Developed a test for Carboxy-methyl-lysine (CML), a biomarker of

advanced glycation end product (A.G.E.) formation, which is believed to

play a part in cardiovascular disease.

-- Initiated two Phase 2 trials with alagebrium for chronic heart failure.

-- Advanced the development of a topical formulation for the use of

SYI-2074 in the treatment of psoriasis.

-- Chosen a lead Glutathione peroxidase mimetic generated in a discovery

collaboration with Provid Pharmaceuticals, that is now being evaluated

for its ability to restore reverse cholesterol transport and treat

atherosclerosis.

-- Strengthened our management team and board of directors with

appointments in research, development and marketin
'/>"/>